476 related articles for article (PubMed ID: 30697897)
1. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
[TBL] [Abstract][Full Text] [Related]
2. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
[TBL] [Abstract][Full Text] [Related]
4. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
[TBL] [Abstract][Full Text] [Related]
5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
[TBL] [Abstract][Full Text] [Related]
8. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
Lin YH; Lin CH; Lin YC; Huang YY; Tai AS; Fu SC; Lin SH
Endocr Pract; 2024 May; 30(5):424-430. PubMed ID: 38325629
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
12. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
[TBL] [Abstract][Full Text] [Related]
13. Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.
Alshnbari A; Alkharaiji M; Anyanwagu U; Idris I
Curr Med Res Opin; 2020 Dec; 36(12):1985-1989. PubMed ID: 33085525
[TBL] [Abstract][Full Text] [Related]
14. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
[TBL] [Abstract][Full Text] [Related]
15. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
17. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
[TBL] [Abstract][Full Text] [Related]
18. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
[TBL] [Abstract][Full Text] [Related]
20. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study.
Wu CY; Iskander C; Wang C; Xiong LY; Shah BR; Edwards JD; Kapral MK; Herrmann N; Lanctôt KL; Masellis M; Swartz RH; Cogo-Moreira H; MacIntosh BJ; Rabin JS; Black SE; Saskin R; Swardfager W
Diabetes Care; 2023 Feb; 46(2):297-304. PubMed ID: 36508692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
